Ensign Peak Advisors’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
Other funds holding XENE
Ensign Peak Advisors's XENE Position: Q3 2026 in Review
Ensign Peak Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q3 2026 at 5,394 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.
Ensign Peak Advisors first reported a position in XENE in Q3 2021 and has held it in 21 quarters since. The position peaked at $7.57M in Q4 2023. 288 funds tracked by Wall St. Rank hold XENE as of Q3 2026.
- Ensign Peak Advisors held 5,394 shares of Xenon Pharmaceuticals worth $201K as of Q3 2026.
- Ensign Peak Advisors left its Xenon Pharmaceuticals share count unchanged in Q3 2026.
- Xenon Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q3 2026, its #1338 holding.
- Ensign Peak Advisors first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 21 quarters since.
- Ensign Peak Advisors's Xenon Pharmaceuticals position peaked at $7.57M in Q4 2023.
- 288 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2026.
Based on Ensign Peak Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.